导管导向硬化治疗卵巢子宫内膜异位囊肿:短期结局
这项前瞻性研究纳入14例原发性或复发性卵巢子宫内膜异位囊肿患者,接受95%乙醇导管导向硬化治疗(CDS)。囊肿平均大小从5.8 cm±2.2降至1.1 cm±1(P<.001),平均随访12.7个月无复发,疼痛均缓解,CA-125下降(P=.001),AMH治疗前后无差异(P>.875),无操作相关并发症。
要点
- CDS后囊肿平均大小由5.8 cm±2.2降至1.1 cm±1(P<.001)。
- 平均随访12.7个月(范围6.1-23.0个月)无囊肿复发。
- 治疗前后AMH无差异(4.29 ng/mL±2.47 vs 4.36 ng/mL±1.94,P>.875),卵巢功能保留良好。
核心结论
- 95%乙醇导管导向硬化治疗可使子宫内膜异位囊肿患者获得更好的短期临床结局并良好保留卵巢功能。
研究设计与样本
- 前瞻性研究,纳入14例(平均年龄32岁,范围20-44岁)于2015年3月至2017年12月接受CDS的原发性或复发性卵巢子宫内膜异位囊肿患者;诊断基于症状和影像学检查;以血清AMH、CA-125及随访超声(CDS后1、3、6个月及此后每半年)评估。
关键影像表现/征象
- 子宫内膜异位囊肿平均大小从CDS前5.8 cm±2.2降至CDS后1.1 cm±1(P<.001)。
- CDS后随访超声用于监测囊肿大小变化和复发,平均随访12.7个月(范围6.1-23.0个月)内无复发。
- 所有参与者疼痛均缓解,血清CA-125水平下降(P=.001)。
诊断标准与关键数值
- 血清AMH在CDS前与CDS后6个月分别为4.29 ng/mL±2.47与4.36 ng/mL±1.94,两者无差异(P>.875),提示卵巢功能保留良好。
- 诊断依据为症状和影像学检查,随访超声于CDS后1、3、6个月及此后每半年进行以监测囊肿大小变化和复发。
临床应用与阅片要点
- 原文结论认为95%乙醇导管导向硬化治疗可为子宫内膜异位囊肿患者带来更好的短期临床结局并良好保留卵巢功能。
- 随访中通过超声监测囊肿大小变化和复发,并同时检测血清AMH与CA-125。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the effectiveness of catheter-directed sclerotherapy (CDS) with 95% ethanol in patients with primary or recurrent ovarian endometriomas. Materials and Methods In this prospective study, 14 participants (mean age, 32 years; range, 20-44 years) who underwent CDS for ovarian endometrioma from March 2015 to December 2017 were evaluated. Diagnosis was based on symptoms and imaging studies. To assess the impact of CDS on ovarian reserve, serum anti-Müllerian hormone (AMH) was measured before CDS and 6 months after CDS. Serum cancer antigen 125 (CA-125) levels were also measured at the same time points. Follow-up US was performed 1, 3, and 6 months after CDS and biannually thereafter to monitor potential cyst size change and recurrence. Comparison of AMH, CA-125, and cyst size before and after CDS was performed by using the paired t test or Wilcoxon signed-rank test. Results Mean endometrioma size decreased from 5.8 cm ± 2.2 to 1.1 cm ± 1 (P ˂ .001). During a mean follow-up of 12.7 months (range, 6.1-23.0 months), there were no recurrences of endometrioma. Pain was relieved in all participants, with a decrease in serum CA-125 level (P = .001). There was no difference in serum AMH level before and 6 months after CDS, indicating well-preserved ovarian function (4.29 ng/mL ± 2.47 vs 4.36 ng/mL ± 1.94, respectively; P > .875). There were no procedure-related complications. Conclusion Catheter-based sclerotherapy with 95% ethanol can lead to better short-term clinical outcomes and well-preserved ovarian function for patients with endometriomas. © RSNA, 2018.
引用
- Han K, Seo SK, Kim MD, et al. Catheter-directed Sclerotherapy for Ovarian Endometrioma: Short-term Outcomes. Radiology. 2018. PMID: 30152743. doi:10.1148/radiol.2018180606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。